NO971566L - Fremgangsmåte for behandling av diabetes mellitus ved anvendelse av KGF - Google Patents

Fremgangsmåte for behandling av diabetes mellitus ved anvendelse av KGF

Info

Publication number
NO971566L
NO971566L NO971566A NO971566A NO971566L NO 971566 L NO971566 L NO 971566L NO 971566 A NO971566 A NO 971566A NO 971566 A NO971566 A NO 971566A NO 971566 L NO971566 L NO 971566L
Authority
NO
Norway
Prior art keywords
kgf
diabetes mellitus
treating diabetes
mammals
diabetes
Prior art date
Application number
NO971566A
Other languages
English (en)
Norwegian (no)
Other versions
NO971566D0 (no
Inventor
Sharon Lea Aukerman
Glenn Francis Pierce
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of NO971566D0 publication Critical patent/NO971566D0/no
Publication of NO971566L publication Critical patent/NO971566L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NO971566A 1994-10-13 1997-04-04 Fremgangsmåte for behandling av diabetes mellitus ved anvendelse av KGF NO971566L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US32334094A 1994-10-13 1994-10-13
US32347594A 1994-10-13 1994-10-13
US48782595A 1995-06-07 1995-06-07
PCT/IB1995/000992 WO1996011950A1 (en) 1994-10-13 1995-10-12 Method of treating diabetes mellitus using kgf

Publications (2)

Publication Number Publication Date
NO971566D0 NO971566D0 (no) 1997-04-04
NO971566L true NO971566L (no) 1997-04-14

Family

ID=27406268

Family Applications (2)

Application Number Title Priority Date Filing Date
NO971566A NO971566L (no) 1994-10-13 1997-04-04 Fremgangsmåte for behandling av diabetes mellitus ved anvendelse av KGF
NO19971568A NO318761B1 (no) 1994-10-13 1997-04-04 Polypeptidanalog til nativ keratinocyttvekstfaktor kalt "KGF", farmasoytisk formulering, rekombinant nukleinsyremolekyl, biologisk funksjonell vektor, prokaryot eller eukaryot vertscelle, fremgangsmate for fremstilling av en analog av KGF, anvendelse av en effektiv mengde av analogen av KGF i folge oppfinnelsen, eller deltaN23 for fremstilling av et medikament for stimulering av produksjon av ikke-fibroblastepitelceller, in vitro fremgangsmate for stimulering av produksjon av ikke-fibroblastepitelceller samt sett.

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO19971568A NO318761B1 (no) 1994-10-13 1997-04-04 Polypeptidanalog til nativ keratinocyttvekstfaktor kalt "KGF", farmasoytisk formulering, rekombinant nukleinsyremolekyl, biologisk funksjonell vektor, prokaryot eller eukaryot vertscelle, fremgangsmate for fremstilling av en analog av KGF, anvendelse av en effektiv mengde av analogen av KGF i folge oppfinnelsen, eller deltaN23 for fremstilling av et medikament for stimulering av produksjon av ikke-fibroblastepitelceller, in vitro fremgangsmate for stimulering av produksjon av ikke-fibroblastepitelceller samt sett.

Country Status (23)

Country Link
EP (2) EP0804479B1 (de)
JP (2) JP4426646B2 (de)
KR (1) KR100278597B1 (de)
CN (1) CN1168678A (de)
AT (2) ATE237633T1 (de)
AU (1) AU3707795A (de)
BG (2) BG101392A (de)
BR (2) BR9509269A (de)
CA (2) CA2201940C (de)
CZ (3) CZ297329B6 (de)
DE (2) DE69535264T2 (de)
DK (2) DK0804479T3 (de)
EE (2) EE9700225A (de)
ES (2) ES2196082T3 (de)
FI (2) FI971420A0 (de)
HU (2) HUT78050A (de)
NO (2) NO971566L (de)
NZ (2) NZ505502A (de)
PL (2) PL320484A1 (de)
PT (2) PT785948E (de)
SI (2) SI0785948T1 (de)
SK (2) SK284534B6 (de)
WO (2) WO1996011950A1 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0555205T3 (da) 1989-01-31 2001-03-05 Jeffrey S Rubin DNA, der koder for en væstfaktor, som er specifik for epitelceller
US7084119B2 (en) 1993-06-29 2006-08-01 Chiron Corporation Truncated keratinocyte growth factor (KGF) having increased biological activity
NZ266622A (en) 1993-06-29 1997-10-24 Chiron Corp Keratinocyte growth factor fragment (kgf) with at least a 2-fold increase in mitogenic activity compared to a full length kgf; dna molecules, expression vectors, host cells, and conjugates
DK0785949T3 (da) * 1994-10-13 2003-08-18 Amgen Inc Fremgangsmåde til oprensning af keratinocytvækstfaktorer
US6693077B1 (en) 1995-02-14 2004-02-17 Human Genome Sciences, Inc. Keratinocyte growth factor-2
US7232667B2 (en) 1995-02-14 2007-06-19 Human Genome Sciences, Inc. Keratinocyte growth factor-2 polynucleotides
US6077692A (en) 1995-02-14 2000-06-20 Human Genome Sciences, Inc. Keratinocyte growth factor-2
EP0822943B9 (de) * 1995-04-27 2007-02-28 Coöperatie Cosun U.A. Derivate von inulin
DE69728415T2 (de) * 1996-10-15 2004-08-12 Amgen Inc., Thousand Oaks Produkte des keratinocyten-wachstumsfaktors 2 (kgf-2)
SI0935652T1 (en) * 1996-10-15 2004-06-30 Amgen Inc. Keratinocyte growth factor-2 products
US6743422B1 (en) 1996-10-15 2004-06-01 Amgen, Inc. Keratinocyte growth factor-2 products
US7153943B2 (en) 1997-07-14 2006-12-26 Bolder Biotechnology, Inc. Derivatives of growth hormone and related proteins, and methods of use thereof
ATE375363T1 (de) 1997-07-14 2007-10-15 Bolder Biotechnology Inc Derivate des wachstumshormons und verwandte proteine
US7495087B2 (en) 1997-07-14 2009-02-24 Bolder Biotechnology, Inc. Cysteine muteins in the C-D loop of human interleukin-11
US20080076706A1 (en) 1997-07-14 2008-03-27 Bolder Biotechnology, Inc. Derivatives of Growth Hormone and Related Proteins, and Methods of Use Thereof
EP1041996A4 (de) 1997-12-22 2003-05-14 Human Genome Sciences Inc Keratinozyten wachstumsfaktor-2 formulierungen
US6869927B1 (en) 1997-12-22 2005-03-22 Human Genome Sciences, Inc. Keratinocyte growth factor-2 formulations
US6242666B1 (en) 1998-12-16 2001-06-05 The Scripps Research Institute Animal model for identifying a common stem/progenitor to liver cells and pancreatic cells
AU775937B2 (en) * 1999-01-14 2004-08-19 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
US8288126B2 (en) 1999-01-14 2012-10-16 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
US6248725B1 (en) 1999-02-23 2001-06-19 Amgen, Inc. Combinations and methods for promoting in vivo liver cell proliferation and enhancing in vivo liver-directed gene transduction
WO2002062842A1 (en) * 2001-02-06 2002-08-15 Merck Patent Gmbh Modified keratinocyte growth factor (kgf) with reduced immunogenicity
MXPA04001526A (es) 2001-08-21 2004-05-31 Chiron Corp Composiciones de polipetidos kgf.
AU2007214362B2 (en) * 2001-08-21 2009-11-26 Novartis Vaccines And Diagnostics, Inc. KGF polypeptide compositions
MX2007006822A (es) 2004-12-15 2007-07-24 Amgen Inc Formulaciones terapeuticas para el factor de crecimiento de queratinocitos.
CN102242124B (zh) * 2010-05-10 2013-05-22 齐鲁制药有限公司 改造的角化细胞生长因子基因及其在酵母中的表达
KR102440312B1 (ko) * 2020-08-28 2022-09-05 한국해양과학기술원 온도안정성을 향상시킨 fgf7 폴리펩타이드 및 그 용도

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4959314A (en) * 1984-11-09 1990-09-25 Cetus Corporation Cysteine-depleted muteins of biologically active proteins
JPH01137994A (ja) * 1987-08-10 1989-05-30 Shionogi & Co Ltd ｒｅｇ蛋白質
CA1306456C (en) * 1988-07-27 1992-08-18 Marjan International Pty. Ltd. Carpet stretcher
DK0555205T3 (da) * 1989-01-31 2001-03-05 Jeffrey S Rubin DNA, der koder for en væstfaktor, som er specifik for epitelceller
JP3303211B2 (ja) * 1991-04-26 2002-07-15 武田薬品工業株式会社 ｂＦＧＦムテインおよびその製造法
HU220641B1 (hu) * 1993-03-26 2002-03-28 Amgen Inc. Keratinocita növekedési faktor alkalmazása
US5348563A (en) * 1993-06-29 1994-09-20 Honeywell Inc. Air purifying apparatus
NZ266622A (en) * 1993-06-29 1997-10-24 Chiron Corp Keratinocyte growth factor fragment (kgf) with at least a 2-fold increase in mitogenic activity compared to a full length kgf; dna molecules, expression vectors, host cells, and conjugates
GB9315501D0 (en) * 1993-07-27 1993-09-08 Ici Plc Surfactant compositions
WO1995003831A1 (en) * 1993-08-02 1995-02-09 Prizm Pharmaceuticals, Inc. Monogenous preparations of cytotoxic conjugates

Also Published As

Publication number Publication date
CZ98197A3 (cs) 1998-11-11
ES2273338T3 (es) 2007-05-01
EP0785948B1 (de) 2003-04-16
AU681546B2 (en) 1997-08-28
CA2201940A1 (en) 1996-04-25
EE9700225A (et) 1998-02-16
JP4216329B2 (ja) 2009-01-28
FI971420L (fi) 1997-04-04
ATE342278T1 (de) 2006-11-15
CA2202075A1 (en) 1996-04-25
NO971566D0 (no) 1997-04-04
SK45597A3 (en) 1999-02-11
NO318761B1 (no) 2005-05-02
DE69535264T2 (de) 2007-02-01
JPH10507193A (ja) 1998-07-14
BG101392A (en) 1997-10-31
CN1168678A (zh) 1997-12-24
ES2196082T3 (es) 2003-12-16
HUT78058A (hu) 1999-07-28
CA2201940C (en) 2009-05-12
BG101408A (bg) 1997-12-30
JP4426646B2 (ja) 2010-03-03
NZ505502A (en) 2005-01-28
WO1996011950A1 (en) 1996-04-25
EE03975B1 (et) 2003-02-17
PL182888B1 (pl) 2002-03-29
KR100278597B1 (ko) 2001-01-15
JPH10507080A (ja) 1998-07-14
HU226168B1 (en) 2008-05-28
EP0785948A1 (de) 1997-07-30
SK284534B6 (sk) 2005-06-02
BR9509269A (pt) 1997-12-23
DE69530403T2 (de) 2003-10-30
EE9700081A (et) 1997-10-15
PL320484A1 (en) 1997-09-29
PT785948E (pt) 2003-09-30
CZ105097A3 (cs) 1998-10-14
FI971536L (fi) 1997-06-09
DE69530403D1 (de) 2003-05-22
AU3707795A (en) 1996-05-06
CZ297329B6 (cs) 2006-11-15
PT804479E (pt) 2007-02-28
WO1996011949A3 (en) 1996-12-12
CA2202075C (en) 2003-12-09
SI0785948T1 (en) 2003-08-31
DK0785948T3 (da) 2003-08-04
NZ335109A (en) 2000-08-25
FI971420A7 (fi) 1997-04-04
EP0804479A1 (de) 1997-11-05
PL319784A1 (en) 1997-08-18
EP0804479B1 (de) 2006-10-11
AU3708395A (en) 1996-05-06
FI120040B (fi) 2009-06-15
NO971568D0 (no) 1997-04-04
BG63167B1 (bg) 2001-05-31
SK43197A3 (en) 1999-03-12
DE69535264D1 (de) 2006-11-23
NO971568L (no) 1997-06-12
CZ297328B6 (cs) 2006-11-15
DK0804479T3 (da) 2007-01-29
SI0804479T1 (sl) 2006-12-31
FI971536A0 (fi) 1997-04-11
BR9509329A (pt) 1997-10-14
HUT78050A (hu) 1999-07-28
ATE237633T1 (de) 2003-05-15
FI971420A0 (fi) 1997-04-04
WO1996011949A2 (en) 1996-04-25

Similar Documents

Publication Publication Date Title
NO971566D0 (no) Fremgangsmåte for behandling av diabetes mellitus ved anvendelse av KGF
NO963785L (no) Fremgangsmåte for behandling av 5HT2B-reseptor-relaterte betingelser
ATE140388T1 (de) Zusammensetzungen enthaltend omega conotoxin peptide derivate und deren verwendung zur behandlung von ischämie-artigen neuronalen schädigungen
AU5729098A (en) Treatment agents and methods for treating type ii diabetes and symptoms of type ii diabetes
NO981810D0 (no) Sammensetninger og fremgangsmÕter for behandling av tilstander ved bensvikt
NO963322D0 (no) Fremgangsmåte for behandling av abstinens ved stoffmisbruk
NO972451L (no) Heterosyklyloksy- og tiometyl-1,2,5-tiadiazolidin-3-on 1,1-dioksyder og preparater og fremgangsmåte for anvendelse derav
FI943028L (fi) Happoa kestävä FGF-koostumus ja menetelmä ruoansulatuskanavassa esiintyvien, haavaumia aiheuttavien sairauksien hoitamiseksi
AU3040795A (en) Method and composition for treating intestinal wounds or ulcers
NO972449L (no) Substituerte 2-arylkarbonyloksymetyl-1,2,5-tiadiazolidin-3-on-1,1-dioksidderivater og preparater og fremgangsmåte for anvendelse derav
SE9600120D0 (sv) Novel medical use
EP0909172A4 (de) Verfahren und zusammensetzungen zur behandlung von harninkontinenz unter verwendung von enantiomer-angereichertem (r,s)-glycopyrrolat
ATE251462T1 (de) Verfahren zur behandlung von narbengewebe
NO963366D0 (no) Peptider og fremgangsmåte for behandling av diabetes
ATE306278T1 (de) Behandlung von knochenleiden mit adrenomedullin
DE69110861D1 (de) Mittel zur verbesserung des kollagenmetabolismus und dessen verwendung.
AUPM836794A0 (en) Improved method and composition for the treatment of ulcers
NO984198D0 (no) Fremgangsmåte for behandling av aggresjon
DE69433055D1 (de) Zusammensetzung zum heilen von verletztem gewebe, verfahren für ihre herstellung und ihre verwendung
UA30448A (uk) Спосіб формування холедоходуоденоанастомозу
AU3597695A (en) Improved method and composition for the treatment of ulcers
AUPN733195A0 (en) Improved method and composition for the treatment of ulcers
IT1285551B1 (it) Composizione e procedimento per la sterilizzazione di substrati di coltura